Paris-based start-up Enodia Therapeutics has secured €20.7 million in seed funding to advance its early-stage pipeline of targeted protein degradation. Elaia, Pfizer Ventures and Bpifrance led the Seed financing under the InnoBio investment framework, with further contributions from Wallonie Entreprendre, Argobio Studio, MACSF, the Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.
Enodia Therapeutics raises €20.7m seed round for targeted protein degradation pipeline
Latest NewsParis-based start-up Enodia Therapeutics has secured €20.7 million in seed funding to advance its early-stage pipeline of targeted protein degradation. Elaia, Pfizer Ventures and Bpifrance led the Seed financing under the InnoBio investment framework, with further contributions from Wallonie Entreprendre, Argobio Studio, MACSF, the Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.
French investor Andera makes a $227m bet on U.S. obesity and asthma innovation
Latest NewsParis-based private equity firm Andera Partners has kicked off 2026 with a surge of cross-border activity, leading two significant Series A financings for U.S. life sciences ventures. The back-to-back rounds of the French investment fund signal a commitment to innovative startups in the United States, where both companies are headquartered and conducting key development operations
TECregen raises €11m seed round to advance thymus regeneration
Latest NewsSwiss biotechnology company TECregen, based in Basel, has raised CHF 10 million (about €11 million) in seed financing to advance therapies designed to restore immune function by regenerating the thymus, an organ central to T-cell development but rarely targeted by drugs.
Billionaire Mike Platt backs Engitix for the second time with a $25 million series A extension
Latest News4 years after its initial series A round, Engitix has completed a $25 million series A extension, led by Netherton Investments, which invests on behalf of billionaire hedge fund founder Mike Platt. The London-based biotech is developing therapies that target the extracellular matrix (ECM) in solid tumors and fibrosis, an area less crowded than more established drug discovery approaches.
Evotec benefits from Dark Blue acquisition by Amgen
Latest NewsThe acquisition of Oxford-based Dark Blue Therapeutics by US biotechnology company Amgen Inc. has produced a German beneficiary: Hamburg-based Evotec SE. Through an early collaboration with the Oxford scientists, Evotec secured an equity stake and will now participate in the proceeds of the transaction.
Basilea strikes up to $48.5m antifungal deal with U.S. biotech Prokaryotics
Latest NewsSwiss anti-infectives specialist Basilea Pharmaceutica has entered a research collaboration with U.S.-based Prokaryotics to develop a novel broad-spectrum antifungal aimed at treating severe invasive fungal infections, the companies announced on January 7th 2026.
Polish biotech JPP Biologics reports positive Phase I data for first-in-class biologic for immune diseases
Latest NewsJJP Biologics has announced positive top-line results from a Phase I clinical trial of JJP-1212, its first-in-class anti-CD89 antagonist being developed for IgA-mediated inflammatory diseases. The data validate the programme’s safety and biological activity and clear the way for Phase II studies starting later this year.
Amgen selects German Disco Pharma to collaborate in multi-million-dollar deal
Latest NewsThe new year at Cologne-based Disco Pharma has begun much as the old one ended: with a headline-grabbing announcement. Just weeks after closing a sizeable financing round, the company has now unveiled an equally notable collaboration with US biotech pioneer Amgen, a partnership with a potential value of up to US$618 million.
Amgen acquires Dark Blue Therapeutics for up to $840 million
Latest NewsAmgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown of the upfront payment alongside development and regulatory milestones was not disclosed in the press release.
LoQus23 moves Huntington’s disease candidate into development
Latest NewsUK-based biotech LoQus23 Therapeutics is advancing an oral small molecule targeting a fundamental genetic process in Huntington’s disease, a rare neurodegenerative disorder.